oxidien
  • 2° Hyperoxaluria
  • Products
  • Team
  • Events
  • Contact
Select Page
Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category

Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category

by demo | Sep 23, 2020 | News, Press Release

Recognized as Early Stage Company with Ground-breaking TechnologyWinning Buzz of BIO gives us an additional boost going into BIO Investor Forum Digital where we will present this opportunity to potential new investors”— Helena CowleyGAINESVILLE, FL, USA, September 23,...
Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate

Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate

by demo | Sep 10, 2020 | News, Press Release

A Prospective, Double-Blind, Randomized, Placebo-Controlled, Cross-Over Study Using a Proprietary Orally Administered Oxalate Decarboxylase (OxDC)GAINESVILLE, FLA, USA, September 10, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage...
OXIDIEN PHARMACEUTICALS ANNOUNCE ADDITION TO SCIENTIFIC AND MEDICAL ADVISORY BOARD

OXIDIEN PHARMACEUTICALS ANNOUNCE ADDITION TO SCIENTIFIC AND MEDICAL ADVISORY BOARD

by demo | Jul 9, 2020 | News, Press Release

GAINESVILLE, FL, USA, July 9, 2020 /EINPresswire.com/ — Oxidien Pharmaceuticals, a clinical-stage biopharmaceutical company developing a best-in-class enzyme therapeutic for an underserved kidney disease indication, today announced three additions to its...
Oxidien in the top 3 at Life Science Nation’s RESI Innovation Challenge.

Oxidien in the top 3 at Life Science Nation’s RESI Innovation Challenge.

by themedev | Jun 26, 2020 | News, Press Release

Oxidien in the top 3 at Life Science Nation’s RESI Innovation Challenge. Read More

Recent Posts

  • Oxidien Pharmaceuticals Selected as Winner of Buzz of BIO in Early Stage Entrepreneur Category
  • Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate
  • OXIDIEN PHARMACEUTICALS ANNOUNCE ADDITION TO SCIENTIFIC AND MEDICAL ADVISORY BOARD
  • Oxidien in the top 3 at Life Science Nation’s RESI Innovation Challenge.
  • Oxidien Chosen to Present at Venture Summit West

Home
Mission Statement
2° Hyperoxaluria
Privacy Statement
Terms Of Use

Products
Team
Events
Contact
References

info@oxidien.com

352.672.5320

747 SW 2nd Avenue, IMB 57
Gainesville, FL 32601

  • Twitter
  • Google

Copyright © 2020 Oxidien Pharmaceuticals, LLC. All Rights Reserved.

Latest News

Oxidien Announces Publication of Clinical Results Demonstrating Significant Reduction in Urinary Oxalate.

Get the early access paper here.



Close
See Our Latest News

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.